Ertapenem

Identification

Are you a

new drug developer?

Contact us to learn more about our customized products and solutions.

Stay in the know!

As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.

#DrugBankUpdates

Name

Ertapenem

Accession Number

DB00303  (APRD00952)

Type

Small Molecule

Groups

Approved, Investigational

Description

Ertapenem is a carbapenem antibiotic drug that is marketed under the trade name Invanz by Merck & Co. pharmaceutical company. It is structurally similar to meropenem and possess a 1-beta-methyl group.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Ertapenem (DB00303)

×

Close

Synonyms

• (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid
• (4R,5S,6S)-3-((3S,5S)-5-((3-carboxyphenyl)carbamoyl)pyrrolidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylic acid
• Ertapenem

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Ertapenem sodium	2T90KE67L0	153773-82-1	ZXNAQFZBWUNWJM-HRXMHBOMSA-M

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Ertapenem	Injection, powder, lyophilized, for solution	1 g/1	Intramuscular; Intravenous	Par Pharmaceutical Inc.	2018-07-26	Not applicable
Ertapenem for Injection	Powder, for solution		Intramuscular; Intravenous	Auro Pharma Inc	Not applicable	Not applicable
Ertapenem for Injection	Powder, for solution		Intramuscular; Intravenous	Mda Inc.	Not applicable	Not applicable
Invanz	Injection, powder, lyophilized, for solution	1 g/1	Intravenous	Merck Sharp & Dohme Corp.	2001-11-21	2018-07-31
Invanz	Injection, powder, lyophilized, for solution	1 g/1	Intramuscular; Intravenous	Merck Sharp & Dohme Corp.	2001-11-21	Not applicable
Invanz	Injection, powder, for solution	1 g	Intravenous	Merck Sharp & Dohme B.V.	2002-04-18	Not applicable
Invanz	Powder, for solution	1 g	Intramuscular; Intravenous	Merck Ltd.	2003-08-27	Not applicable
Invanz	Injection, powder, for solution	1 g	Intravenous	Merck Sharp & Dohme B.V.	2002-04-18	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Ertapenem	Injection, powder, lyophilized, for solution	1 g/1	Intramuscular; Intravenous	Fresenius Kabi USA, LLC	2019-10-10	Not applicable
Ertapenem	Injection	1 g/20mL	Intramuscular; Intravenous	Apotex Corp	2019-04-02	Not applicable
Ertapenem	Injection	1 g/20mL	Intramuscular; Intravenous	Savior Lifetec Corporation	2019-03-19	Not applicable
Ertapenem	Injection	1 g/1	Intramuscular; Intravenous	AuroMedics Pharma LLC	2018-06-25	Not applicable
Ertapenem	Injection	1 g/20mL	Intramuscular; Intravenous	BluePoint Laboratories	2019-08-29	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Categories

• Amides
• Anti-Bacterial Agents
• Anti-Infective Agents
• Antibacterials for Systemic Use
• Antiinfectives for Systemic Use
• beta-Lactams
• Carbapenems
• Drugs that are Mainly Renally Excreted
• Heterocyclic Compounds, Fused-Ring
• Lactams
• Penem Antibacterial
• Sulfur Compounds

UNII

G32F6EID2H

CAS number

153832-46-3

Weight

Average: 475.515
Monoisotopic: 475.141320859

Chemical Formula

C₂₂H₂₅N₃O₇S

InChI Key

JUZNIMUFDBIJCM-ANEDZVCMSA-N

InChI

InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1

IUPAC Name

(4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

SMILES

[H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@@]([H])(C3)C(=O)NC3=CC=CC(=C3)C(O)=O)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O

Pharmacology

Indication

For the treatment the following moderate to severe infections caused by susceptible isolates of the designated microorganisms: (1) complicated intra-abdominal infections due to Escherichia coli, Clostridium clostridioforme, Eubacterium lentum, Peptostreptococcus species, Bacteroides fragilis, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, or Bacteroides uniformis, (2) complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis due to Staphylococcus aureus (methicillin susceptible isolates only), Streptococcus agalactiae, Streptococcus pyogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Bacteroides fragilis, Peptostreptococcus species, Porphyromonas asaccharolytica, or Prevotella bivia, (3) community acquired pneumonia due to Streptococcus pneumoniae (penicillin susceptible isolates only) including cases with concurrent bacteremia, Haemophilus influenzae (beta-lactamase negative isolates only), or Moraxella catarrhalis, (4) complicated urinary tract infections including pyelonephritis due to Escherichia coli, including cases with concurrent bacteremia, or Klebsiella pneumoniae, (5) acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections due to Streptococcus agalactiae, Escherichia coli, Bacteroides fragilis, Porphyromonas asaccharolytica, Peptostreptococcus species, or Prevotella bivia.

Associated Conditions

• Community Acquired Pneumonia (CAP)
• Endomyometritis
• Gynaecological infection
• Pelvic Infections
• Pyelonephritis
• Septic Abortion
• Surgical Site Infections
• Severe Intra-abdominal Infections
• Severe Urinary tract infection
• Skin-structure infections

Pharmacodynamics

Ertapenem has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria.

Mechanism of action

The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. Ertapenem is hydrolyzed by metallo-beta-lactamases.

Target	Actions	Organism
APenicillin-binding protein 2	inhibitor	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
APenicillin-binding protein 2	inhibitor	Escherichia coli (strain K12)
APeptidoglycan synthase FtsI	inhibitor	Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
APeptidoglycan synthase FtsI	inhibitor	Escherichia coli (strain K12)
AD-alanyl-D-alanine carboxypeptidase DacB	inhibitor	Escherichia coli (strain K12)
APenicillin-binding protein 1A	inhibitor	Escherichia coli (strain K12)
APenicillin-binding protein 1B	inhibitor	Escherichia coli (strain K12)
AD-alanyl-D-alanine carboxypeptidase DacC	inhibitor	Escherichia coli (strain K12)

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Ertapenem is almost completely absorbed following intramuscular administration. The bioavailability of a 1 g intramuscular dose approximated 92% in 26 healthy subjects [77% male; median (range) age, 29 (22–41) years]. Plasma concentrations of total ertapenem were similar whether given intramuscularly or intravenously.

Volume of distribution

• 0.12 liter/kg [adults]
• 0.2 liter/kg [pediatric, 3 months to 12 years]
• 0.16 liter/kg [pediatric patients 13 to 17 years]

Protein binding

Ertapenem is highly bound to human plasma proteins, primarily albumin, in a concentration-dependent manner. The protein binding of ertapenem decreases as plasma concentrations increase. At a plasma concentration of <100 µg/mL, approximately 95% of ertapenem is protein bound. Protein binding of ertapenem decreases to approximately 85% at an approximate plasma concentration of 300 µg/mL.

Metabolism

The major metabolite is the inactive ring-opened derivative formed by hydrolysis of the β-lactam ring. Ertapenem did not inhibit metabolism mediated by cytochrome P450 (CYP) isoforms 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 when evaluated by in vitro studies in human liver microsomes. Ertapenem is neither a substrate nor an inhibitor of P-glycoprotein or cytochrome P450 enzymes; significant drug interactions between ertapenem and drugs handled by these systems are not expected [PMID: 15150180]

Route of elimination

Of the 80% recovered in urine, approximately 38% is excreted as unchanged drug and approximately 37% as the ring-opened metabolite.

Half life

The mean plasma half-life is approximately 4 hours.

Clearance

• 1.8 L/h

Toxicity

Not Available

Affected organisms

• Enteric bacteria and other eubacteria

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• All Drugs
• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental

Drug	Interaction
Unlock Additional Data
(R)-warfarin	The risk or severity of bleeding can be increased when Ertapenem is combined with (R)-warfarin.
(S)-Warfarin	The risk or severity of bleeding can be increased when Ertapenem is combined with (S)-Warfarin.
4-hydroxycoumarin	The risk or severity of bleeding can be increased when Ertapenem is combined with 4-hydroxycoumarin.
Abacavir	Ertapenem may decrease the excretion rate of Abacavir which could result in a higher serum level.
Acarbose	Acarbose may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Aceclofenac	Aceclofenac may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Acenocoumarol	The risk or severity of bleeding can be increased when Ertapenem is combined with Acenocoumarol.
Acetaminophen	Ertapenem may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

Not Available

References

Synthesis Reference

Ying Shi, Kun Li, Zan Xie, Xuebin Zhao, Jian Lv, Xiuqin Yu, "INTERMEDIATE OF ERTAPENEM, A COMPOSITION COMPRISING THE SAME AND PREPARATION METHODS THEREOF." U.S. Patent US20120095209, issued April 19, 2012.

US20120095209

General References

1. Nix DE, Majumdar AK, DiNubile MJ: Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii23-8. [PubMed:15150180]

External Links

Human Metabolome Database

HMDB0014448

KEGG Drug

D07908

PubChem Compound

150610

PubChem Substance

46506508

ChemSpider

132758

ChEBI

404903

ChEMBL

CHEMBL1359

Therapeutic Targets Database

DAP000431

PharmGKB

PA164777032

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

Wikipedia

Ertapenem

ATC Codes

J01DH03 — Ertapenem

• J01DH — Carbapenems
• J01D — OTHER BETA-LACTAM ANTIBACTERIALS
• J01 — ANTIBACTERIALS FOR SYSTEMIC USE
• J — ANTIINFECTIVES FOR SYSTEMIC USE

AHFS Codes

• 08:12.07.08 — Carbapenems

FDA label

Download (140 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Treatment	Acute, uncomplicated Appendicitis	1
1	Completed	Health Services Research	Healthy Volunteers	1
1	Terminated	Treatment	Endometritis	1
2	Completed	Other	End Stage Renal Disease (ESRD)	1
2	Completed	Other	PK of Ertapenem in TB Patients	1
2	Completed	Treatment	Community Acquired Pneumonia (CAP)	1
2	Completed	Treatment	Complicated Intra-Abdominal Infections	1
2	Completed	Treatment	Infection NOS / Pelvic Infections	1
2	Completed	Treatment	Pneumonia, Bacterial / Soft Tissues Infections / Urinary Tract Infection	1
2	Not Yet Recruiting	Treatment	Appendicitis Acute	1
2	Recruiting	Treatment	Acute Pyelonephritis / Infection Due to Escherichia Coli	1
2, 3	Completed	Prevention	Surgical Site Infections	1
2, 3	Recruiting	Treatment	Anti-Infective Agents, Urinary / Infection Due to Escherichia Coli / Klebsiella Infections / Transplantation, Kidney / Urinary Tract Infection	1
3	Active Not Recruiting	Treatment	Antibiotic Resistant Infection / Complicated skin infection bacterial / Complicated Urinary Tract Infection / Urinary Tract Infection	1
3	Completed	Prevention	Infection NOS / Surgical Site Infections	1
3	Completed	Prevention	Surgery, Colorectal	1
3	Completed	Treatment	Bacterial Infections / Diabetic Foot / Osteomyelitis	1
3	Completed	Treatment	Complicated Intra-Abdominal Infections	1
3	Completed	Treatment	Complicated Urinary Tract Infection	1
3	Completed	Treatment	Foot Infections in Diabetic Patients	1
3	Completed	Treatment	Infection NOS	1
3	Completed	Treatment	Infection NOS / Pneumonia / Urinary Tract Infection	1
3	Completed	Treatment	Infection; Diabetic Foot	1
3	Completed	Treatment	Intraabdominal Infections	1
3	Completed	Treatment	Sepsis	1
3	Completed	Treatment	Urinary Tract Infection	2
3	Recruiting	Treatment	Acute Pyelonephritis / Complicated Urinary Tract Infection	1
3	Recruiting	Treatment	Antibiotic Resistant Infection / Complicated skin infection bacterial / Intra Abdominal Infections	1
3	Recruiting	Treatment	Enterobacteriaceae Infections	1
3	Recruiting	Treatment	Gonorrhea	1
3	Recruiting	Treatment	Urinary Tract Infection	1
3	Terminated	Treatment	Urinary Tract Infection	1
3	Unknown Status	Treatment	Community Acquired Pneumonia (CAP)	1
4	Active Not Recruiting	Treatment	Patients With Urosepis and Received Ertapenem for Treatment	1
4	Completed	Not Available	Acute Renal Failure (ARF)	1
4	Completed	Not Available	Continuous ambulatory peritoneal dialysis therapy / End Stage Renal Disease (ESRD)	1
4	Completed	Not Available	Healthy Volunteers	1
4	Completed	Not Available	Infection NOS	1
4	Completed	Prevention	Benign Prostatic Hyperplasia (BPH) Requiring Surgical Resection	1
4	Completed	Treatment	Burn Patients	1
4	Completed	Treatment	Colonic Neoplasms / Diverticulosis, Colonic / Rectal Neoplasms	1
4	Completed	Treatment	Complicated Intra-Abdominal Infections	1
4	Completed	Treatment	Intra-Abdominal Infections	1
4	Completed	Treatment	Liver Abscess, Pyogenic	1
4	Not Yet Recruiting	Treatment	Antibiotic Resistance, Bacterial / Carbapenem / Clinical Trial / Enterobacteriaceae Infections / Infection Due to ESBL Bacteria / Infection Due to Escherichia Coli / Klebsiella Pneumoniae Infection / Urinary Tract Infection	1
4	Recruiting	Prevention	Fevers / Gastric Varix / Liver Cirrhoses / Sepsis	1
4	Terminated	Treatment	To Assess the Tissular and Plasma Kinetics of Ertapenem	1
4	Unknown Status	Not Available	Allergies / IgE-Mediated Hypersensitivity	1
4	Unknown Status	Educational/Counseling/Training	Acute Disease / Diverticulitis, Colonic	1
4	Unknown Status	Treatment	Acute Appendicitis Without Peritonitis	1
4	Unknown Status	Treatment	Drug Safety	1
Not Available	Active Not Recruiting	Treatment	Appendicitis Acute	1
Not Available	Completed	Treatment	Perforated Appendicitis	1
Not Available	Enrolling by Invitation	Other	Appendicitis Acute	1
Not Available	Enrolling by Invitation	Treatment	Appendicitis Acute	1
Not Available	Recruiting	Not Available	Bacteremia / Bacterial Infections	1
Not Available	Recruiting	Treatment	Appendicitis	1
Not Available	Recruiting	Treatment	Appendicitis Acute	1
Not Available	Unknown Status	Not Available	Urinary Tract Infection	1
Not Available	Withdrawn	Treatment	Amputations	1

Pharmacoeconomics

Manufacturers

• Merck and co inc

Packagers

• Merck & Co.

Dosage forms

Form	Route	Strength
Injection	Intramuscular; Intravenous	1 g/20mL
Injection	Intramuscular; Intravenous	1 g/1
Powder, for solution	Intramuscular; Intravenous
Powder	Not applicable	1 kg/1kg
Injection, powder, for solution	Intravenous	1 g
Injection, powder, lyophilized, for solution	Intramuscular; Intravenous	1 g/1
Injection, powder, lyophilized, for solution	Intravenous	1 g/1
Powder, for solution	Intramuscular; Intravenous	1 g

Prices

Unit description	Cost	Unit
Invanz 1 gm add-vantage vial	72.85USD	vial
Invanz 1 gm vial	69.4USD	vial

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
Unlock Additional Data
US5652233	No	1997-07-29	2013-02-02
CA2106370	No	2003-11-25	2013-02-02
US5478820	Yes	1995-12-26	2016-05-21
US5952323	Yes	1999-09-14	2017-11-15

Additional Data Available

Filed On
Filed On
The date on which a patent was filed with the relevant government.
Learn more

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Soluble as sodium salt	Not Available
logP	0.3	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.286 mg/mL	ALOGPS
logP	-0.2	ALOGPS
logP	-3.2	ChemAxon
logS	-3.2	ALOGPS
pKa (Strongest Acidic)	3.22	ChemAxon
pKa (Strongest Basic)	9.03	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	5	ChemAxon
Polar Surface Area	156.27 Å2	ChemAxon
Rotatable Bond Count	7	ChemAxon
Refractivity	121.8 m3·mol-1	ChemAxon
Polarizability	48.77 Å3	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.5982
Blood Brain Barrier	-	0.9811
Caco-2 permeable	-	0.7052
P-glycoprotein substrate	Substrate	0.7716
P-glycoprotein inhibitor I	Non-inhibitor	0.917
P-glycoprotein inhibitor II	Non-inhibitor	0.9955
Renal organic cation transporter	Non-inhibitor	0.9253
CYP450 2C9 substrate	Non-substrate	0.7891
CYP450 2D6 substrate	Non-substrate	0.8229
CYP450 3A4 substrate	Non-substrate	0.5
CYP450 1A2 substrate	Non-inhibitor	0.8677
CYP450 2C9 inhibitor	Non-inhibitor	0.867
CYP450 2D6 inhibitor	Non-inhibitor	0.8964
CYP450 2C19 inhibitor	Non-inhibitor	0.8511
CYP450 3A4 inhibitor	Non-inhibitor	0.9658
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9695
Ames test	Non AMES toxic	0.6766
Carcinogenicity	Non-carcinogens	0.8052
Biodegradation	Not ready biodegradable	0.9821
Rat acute toxicity	2.0803 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9947
hERG inhibition (predictor II)	Non-inhibitor	0.8848

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as thienamycins. These are beta-lactam antibiotics that differ from penicillins in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Lactams

Sub Class

Beta lactams

Direct Parent

Thienamycins

Alternative Parents

Acylaminobenzoic acid and derivatives / Proline and derivatives / Alpha amino acid amides / Anilides / Benzoic acids / Pyrroline carboxylic acids / Pyrrolidinecarboxamides / Benzoyl derivatives / N-arylamides / AzepinesVinylogous thioesters / Dicarboxylic acids and derivatives / Tertiary carboxylic acid amides / Thioenol ethers / Amino acids / Secondary carboxylic acid amides / Secondary alcohols / Azetidines / Azacyclic compounds / Sulfenyl compounds / Carboxylic acids / Dialkylamines / Organopnictogen compounds / Organic oxides / Carbonyl compounds / Hydrocarbon derivatives

show 16 more

Substituents

Thienamycin / Acylaminobenzoic acid or derivatives / Proline or derivatives / Alpha-amino acid amide / Alpha-amino acid or derivatives / Benzoic acid or derivatives / Benzoic acid / Anilide / Benzoyl / Pyrrolidine carboxylic acid or derivativesPyrrolidine-2-carboxamide / Pyrroline carboxylic acid / Pyrroline carboxylic acid or derivatives / N-arylamide / Azepine / Vinylogous thioester / Benzenoid / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Tertiary carboxylic acid amide / Pyrroline / Pyrrolidine / Amino acid / Thioenolether / Secondary carboxylic acid amide / Secondary alcohol / Amino acid or derivatives / Azetidine / Carboxamide group / Azacycle / Secondary amine / Sulfenyl compound / Carboxylic acid derivative / Carboxylic acid / Secondary aliphatic amine / Alcohol / Organic oxide / Organopnictogen compound / Organosulfur compound / Organic nitrogen compound / Organic oxygen compound / Carbonyl group / Organooxygen compound / Amine / Hydrocarbon derivative / Organonitrogen compound / Aromatic heteropolycyclic compound

show 37 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

pyrrolidinecarboxamide, carbapenemcarboxylic acid (CHEBI:404903)

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on June 13, 2005 07:24 / Updated on December 09, 2019 19:12